Soligenix Reports Positive Preclinical Data With Filovirus Vaccine Candidates

(RTTNews) - Soligenix, Inc. (SNGX) reported positive data showing the efficacy of multiple filovirus vaccine candidates in non-human primates, including thermostabilized multivalent vaccines in a single vial platform presentation. The vaccine candidates contain highly purified protein antigens combined with CoVaccine HT adjuvant, in both monovalent (single antigen) and bivalent (two antigen) formulations.

The thermostabilized filovirus vaccine program is supported by a National Institute of Health grant R01-AI132323 awarded to the University of Hawaii and a Small Business Innovation Research grant awarded to Soligenix.